Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot multiple sclerosis (MS) imaging study conducted with Massachusetts General Hospital. Preliminary PET imaging data from the study show encouraging signals in acute MS lesions, according to a recent article. This milestone comes as the company advances its investigational compound Lucid-MS, which aims to inhibit demyelination by targeting the enzyme PAD2.
The novel imaging technique is designed to distinguish demyelinated nerve fibers that may still be viable from permanent nerve damage, offering a potentially more precise way to measure myelin loss and repair. This distinction could be crucial for monitoring disease progression and evaluating the efficacy of therapies aimed at remyelination. The preliminary data suggest that the imaging approach is capable of detecting meaningful biological signals, which is a positive indicator for the study’s overall validity.
“These findings are directly relevant to Lucid-MS, the company’s investigational compound designed to inhibit demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation,” the article reads. “A more precise imaging tool and a drug candidate designed to address the underlying cause of MS make for a compelling combination. Reaching the enrollment midpoint with promising early data suggests the science is holding up under real clinical conditions.”
The significance of this development lies in the potential to transform how MS is diagnosed and treated. Current diagnostic methods often rely on MRI, which cannot reliably differentiate between active inflammation, chronic lesions, and areas of remyelination. The new PET imaging technique could provide a more accurate biomarker for myelin integrity, enabling clinicians to tailor treatments to individual patients and assess whether therapies are actually promoting repair.
For Quantum BioPharma, the successful advancement of this imaging study is integral to the development of Lucid-MS. If the imaging technique proves effective, it could serve as a companion diagnostic, helping to identify patients who are most likely to benefit from Lucid-MS and to monitor their response to treatment. This could streamline clinical trials and potentially accelerate regulatory approval.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
In addition to its MS program, Quantum BioPharma has developed unbuzzd, a product aimed at reducing alcohol cravings, and has spun out its OTC version to Unbuzzd Wellness Inc. The company retains a 19.84% ownership stake in UWI (as of March 31, 2026) and is entitled to royalty payments of 7% of sales from unbuzzd until payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM.
